Drug-induced nonautoimmune hemolytic anemia

Jump to navigation Jump to search
Drug-induced nonautoimmune hemolytic anemia
ICD-10 D59.2
ICD-9 283

WikiDoc Resources for Drug-induced nonautoimmune hemolytic anemia

Articles

Most recent articles on Drug-induced nonautoimmune hemolytic anemia

Most cited articles on Drug-induced nonautoimmune hemolytic anemia

Review articles on Drug-induced nonautoimmune hemolytic anemia

Articles on Drug-induced nonautoimmune hemolytic anemia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Drug-induced nonautoimmune hemolytic anemia

Images of Drug-induced nonautoimmune hemolytic anemia

Photos of Drug-induced nonautoimmune hemolytic anemia

Podcasts & MP3s on Drug-induced nonautoimmune hemolytic anemia

Videos on Drug-induced nonautoimmune hemolytic anemia

Evidence Based Medicine

Cochrane Collaboration on Drug-induced nonautoimmune hemolytic anemia

Bandolier on Drug-induced nonautoimmune hemolytic anemia

TRIP on Drug-induced nonautoimmune hemolytic anemia

Clinical Trials

Ongoing Trials on Drug-induced nonautoimmune hemolytic anemia at Clinical Trials.gov

Trial results on Drug-induced nonautoimmune hemolytic anemia

Clinical Trials on Drug-induced nonautoimmune hemolytic anemia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Drug-induced nonautoimmune hemolytic anemia

NICE Guidance on Drug-induced nonautoimmune hemolytic anemia

NHS PRODIGY Guidance

FDA on Drug-induced nonautoimmune hemolytic anemia

CDC on Drug-induced nonautoimmune hemolytic anemia

Books

Books on Drug-induced nonautoimmune hemolytic anemia

News

Drug-induced nonautoimmune hemolytic anemia in the news

Be alerted to news on Drug-induced nonautoimmune hemolytic anemia

News trends on Drug-induced nonautoimmune hemolytic anemia

Commentary

Blogs on Drug-induced nonautoimmune hemolytic anemia

Definitions

Definitions of Drug-induced nonautoimmune hemolytic anemia

Patient Resources / Community

Patient resources on Drug-induced nonautoimmune hemolytic anemia

Discussion groups on Drug-induced nonautoimmune hemolytic anemia

Patient Handouts on Drug-induced nonautoimmune hemolytic anemia

Directions to Hospitals Treating Drug-induced nonautoimmune hemolytic anemia

Risk calculators and risk factors for Drug-induced nonautoimmune hemolytic anemia

Healthcare Provider Resources

Symptoms of Drug-induced nonautoimmune hemolytic anemia

Causes & Risk Factors for Drug-induced nonautoimmune hemolytic anemia

Diagnostic studies for Drug-induced nonautoimmune hemolytic anemia

Treatment of Drug-induced nonautoimmune hemolytic anemia

Continuing Medical Education (CME)

CME Programs on Drug-induced nonautoimmune hemolytic anemia

International

Drug-induced nonautoimmune hemolytic anemia en Espanol

Drug-induced nonautoimmune hemolytic anemia en Francais

Business

Drug-induced nonautoimmune hemolytic anemia in the Marketplace

Patents on Drug-induced nonautoimmune hemolytic anemia

Experimental / Informatics

List of terms related to Drug-induced nonautoimmune hemolytic anemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Drug-induced nonautoimmune hemolytic anaemia is a form of hemolytic anaemia.

Non-immune drug induced hemolysis can occur via oxidative mechanisms. This is particularly likely to occur when there is an enzyme deficiency in the antioxidant defence system of the red blood cells. An example is where antimalarial oxidant drugs like primaquine[1] damage red blood cells in Glucose-6-phosphate dehydrogenase deficiency in which the red blood cells are more susceptible to oxidative stress due to reduced NADPH production consequent to the enzyme deficiency.

Some drugs cause RBC (red blood cell) lysis even in normal individuals. These include dapsone[2] and sulfasalazine.

Non-immune drug-induced hemolysis can also arise from drug-induced damage to cell volume control mechanisms; for example drugs can directly or indirectly impair regulatory volume decrease mechanisms, which become activated during hypotonic RBC swelling to return the cell to a normal volume. The consequence of the drugs actions are irreversible cell swelling and lysis (e.g. ouabain at very high doses).

References

  1. Bowman ZS, Oatis JE, Whelan JL, Jollow DJ, McMillan DC (2004). "Primaquine-induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine". J. Pharmacol. Exp. Ther. 309 (1): 79–85. doi:10.1124/jpet.103.062984. PMID 14724225. Unknown parameter |month= ignored (help)
  2. Jollow DJ, Bradshaw TP, McMillan DC (1995). "Dapsone-induced hemolytic anemia". Drug Metab. Rev. 27 (1–2): 107–24. PMID 7641572.

Template:Hematology




Template:WikiDoc Sources